Humanwell Healthcare announced that its holding subsidiary, Yichang Humanwell Pharmaceutical Co.,Ltd., has received the "Acceptance Notice" issued by the National Medical Products Administration for the registration and approval of the market launch of fentanyl citrate oral patches. This product is suitable for treating breakthrough pain in adult cancer patients who are continuously using opioid drugs. As of now, Yichang Humanwell has invested approximately RMB 30 million in this project. Currently, there are no similar products on the market domestically. The acceptance of this application signifies that the domestic production drug registration work for this variety has entered the review stage, and the company will actively promote subsequent related work. If the review and approval process goes smoothly, it will enrich the company's product line and help enhance its market competitiveness.